Drugs / DZD2269
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04932005 | Jun 2021 → Apr 2022 | — | Dizal Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04634344 | Apr 2021 → May 2022 | castration-resistant prostate carcinoma | Dizal Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-10-18 | Dizal Pharmaceuticals | Results Dizal Announces the Latest Publication of DZD2269 in Journal of Experimental & Clinical Cancer Research dizalpharma.com ↗
DZD2269 alone showed anti-tumor activity in immunocompetent mouse models, and when in combination with radiotherapy, chemotherapy, or immune checkpoint inhibitors, its anti-tumor effect was significantly enhanced. |
| 2022-05-27 | Dizal Pharmaceuticals | Results Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022 dizalpharma.com ↗
Results from the Phase 1 healthy volunteer trial, which is evaluating the safety, PK, and effect on biomarkers, showed DZD2269 was safe and well tolerated from 5 mg to 160 mg, with no ≥ grade 3 TEAE or SAE reported. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-10-18 | Dizal Pharmaceuticals | Dizal Announces the Latest Publication of DZD2269 in Journal of Experimental & Clinical Cancer Research dizalpharma.com ↗ |
| 2022-05-27 | Dizal Pharmaceuticals | Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022 dizalpharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DZD2269 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04634344 ↗ |
| Action | Inhibit | “DZD2269, a novel A2aR antagonist which can fully block A2aR mediated immunosuppression commonly found in TME.” PMID 36229853 ↗ Oct 2022 |
| Route | Oral | “Part A: A single oral dose at 5mg, 10mg, 20mg, 40mg, 80mg, 160mg.” NCT04932005 ↗ |
| Target | ADORA2A | “DZD2269, a novel A2aR antagonist which can fully block A2aR mediated immunosuppression commonly found in TME.” PMID 36229853 ↗ Oct 2022 |